Xenograft Model Antitumor Assays

"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Descriptor ID	D023041
MeSH Number(s)	E05.337.550.200.900 E05.624.850
Concept/Terms	Xenograft Model Antitumor Assays Xenograft Model Antitumor Assays Tumor Xenograft Assay Xenograft Antitumor Assays Antitumor Assay, Xenograft Antitumor Assays, Xenograft Assay, Xenograft Antitumor Assays, Xenograft Antitumor Xenograft Antitumor Assay Antitumor Assays, Xenograft Model

Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]
Xenograft Model Antitumor Assays [E05.337.550.200.900]
Neoplasm Transplantation [E05.624]
Xenograft Model Antitumor Assays [E05.624.850]

Below are MeSH descriptors whose meaning is related to "Xenograft Model Antitumor Assays".

Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".

Xenograft Model Antitumor Assays
Subrenal Capsule Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.

Bar chart showing 139 publications over 22 distinct years, with a maximum of 16 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	4	4
2004	0	1	1
2005	1	2	3
2006	0	3	3
2007	0	3	3
2008	0	4	4
2009	0	3	3
2010	1	12	13
2011	1	9	10
2012	1	2	3
2013	0	8	8
2014	0	9	9
2015	1	11	12
2016	1	10	11
2017	0	16	16
2018	0	13	13
2019	1	5	6
2020	0	3	3
2021	0	7	7
2022	0	1	1
2024	2	3	5
2025	0	1	1

Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.

Banday S, Mishra AK, Rashid R, Ye T, Ali A, Li J, Yustein JT, Kelliher MA, Zhu LJ, Deibler SK, Malonia SK, Green MR. The O-glycosyltransferase C1GALT1 promotes EWSR1::FLI1 expression and is a therapeutic target for Ewing sarcoma. Nat Commun. 2025 Feb 02; 16(1):1267.

View in: PubMed
Rozen EJ, Frantz W, Wigglesworth K, Vessella T, Zhou HS, Shohet JM. Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis. Mol Cancer Ther. 2024 Aug 01; 23(8):1124-1138.

View in: PubMed
Sicinska E, Kola VSR, Kerfoot JA, Taddei ML, Al-Ibraheemi A, Hsieh YH, Church AJ, Landesman-Bollag E, Landesman Y, Hemming ML. ASPSCR1::TFE3 Drives Alveolar Soft Part Sarcoma by Inducing Targetable Transcriptional Programs. Cancer Res. 2024 Jul 15; 84(14):2247-2264.

View in: PubMed
Assatova B, Willim R, Trevisani C, Haskett G, Kariya KM, Chopra K, Park SR, Tolstorukov MY, McCabe SM, Duffy J, Louissaint A, Huuhtanen J, Bhattacharya D, Mustjoki S, Koh MJ, Powers F, Morgan EA, Yang L, Pinckney B, Cotton MJ, Crabbe A, Ziemba JB, Brain I, Heavican-Foral TB, Iqbal J, Nemec R, Rider AB, Ford JG, Koh MJ, Scanlan N, Feith DJ, Loughran TP, Kim WS, Choi J, Roels J, Boehme L, Putteman T, Taghon T, Barnes JA, Johnson PC, Jacobsen ED, Greenberg SA, Weinstock DM, Jain S. KLRG1 Cell Depletion as a Novel Therapeutic Strategy in Patients with Mature T-Cell Lymphoma Subtypes. Clin Cancer Res. 2024 Jun 03; 30(11):2514-2530.

View in: PubMed
Sarli SL, Fakih HH, Kelly K, Devi G, Rembetsy-Brown JM, McEachern HR, Ferguson CM, Echeverria D, Lee J, Sousa J, Sleiman HF, Khvorova A, Watts JK. Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo. Nucleic Acids Res. 2024 May 22; 52(9):4799-4817.

View in: PubMed
Ye T, Mishra AK, Banday S, Li R, Hu K, Coleman MM, Shan Y, Chowdhury SR, Zhou L, Pak ML, Simone TM, Malonia SK, Zhu LJ, Kelliher MA, Green MR. Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. Cell Rep. 2024 05 28; 43(5):114211.

View in: PubMed
Cornelius P, Mayes BA, Petersen JS, Turnquist DJ, Dufour PJ, Dannenberg AJ, Shanahan JM, Carver BJ. Pharmacological Characterization of SDX-7320/Evexomostat: A Novel Methionine Aminopeptidase Type 2 Inhibitor with Anti-tumor and Anti-metastatic Activity. Mol Cancer Ther. 2024 May 02; 23(5):595-605.

View in: PubMed
Hickman TL, Choi E, Whiteman KR, Muralidharan S, Pai T, Johnson T, Parikh A, Friedman T, Gilbert M, Shen B, Barron L, McGinness KE, Ettenberg SA, Motz GT, Weiss GJ, Jensen-Smith A. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity. PLoS One. 2022; 17(5):e0266980.

View in: PubMed
Herzog AE, Warner KA, Zhang Z, Bellile E, Bhagat MA, Castilho RM, Wolf GT, Polverini PJ, Pearson AT, N?r JE. The IL-6R and Bmi-1 axis controls self-renewal and chemoresistance of head and neck cancer stem cells. Cell Death Dis. 2021 10 23; 12(11):988.

View in: PubMed
Szydlowski M, Garbicz F, Jablonska E, G?rniak P, Komar D, Pyrzynska B, Bojarczuk K, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Rymkiewicz G, Cybulska M, Statkiewicz M, Gajewska M, Mikula M, Golas A, Domagala J, Winiarska M, Graczyk-Jarzynka A, Bialopiotrowicz E, Polak A, Barankiewicz J, Pula B, Pawlak M, Nowis D, Golab J, Tomirotti AM, Brz?zka K, Pacheco-Blanco M, Kupcova K, Green MR, Havranek O, Chapuy B, Juszczynski P. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Res. 2021 12 01; 81(23):6029-6043.

View in: PubMed

People

Explore

Similar Concepts

Top Journals